Total Committed: $3,083,428
Total Funded: $2,048,428
Institution
Year
Committed
Funded
Researcher
Description
2024
$50,000
$50,000
Dr. Laura Hsieh
TippingPoint Biosciences is an early-stage therapeutic company with a novel drug discovery platform to identify first-in-class drugs aimed at treating diseases related to dysfunctional DNA packaging (chromatin). TippingPoint Bio is the first to develop a screening platform to enable direct targeting of the defective chromatin in disease cells without affecting healthy cells.
2024
$77,428
$77,428
Dr. David Daniels
Dr. Yuqian Yan
Targeting H3.3S28ph as a Novel Therapeutic Strategy for DMG
Study will further investigate the molecular interplay between K27M and S28ph and evaluate if targeting H3.3S28ph using Alisertib is an effective strategy for DMG treatment.
2024
$625,000
$225,000
Dr. Michelle Monje
Neural Mechanisms Affecting CAR T Cell Therapy in DMG
This research will test the effects of neural signaling molecules on CAR T cell fitness and function, test the effects of these same neural signaling molecules on other immune cells that can strongly interfere with CAR T-cell function, and target the relevant neural signaling pathways to improve CAR T-cell efficacy against DMG.
Post Doctoral Fellowship - Vrunda Trivedi
2023
2024
$120,000
$33,000
$60,000
$33,000
Dr. John Prensner
De novo discovery of novel protein-coding regions in DIPG
This project will provide a customized analysis of the DIPG genome, focused on systematically defining regions of microprotein translation. It will be the first attempt to fully catalogue the extent of protein-coding genes in DIPG.
2024
2023
2022
$1,000,000
$100,000
$200,000
$200,000
Dr. Carl Koschmann
Translation of EGFR inhibitor to DMG
An investigative study will be conducted to comprehensively assess the CNS penetration, preliminary efficacy and safety of small molecule EGFR inhibitors at the pre-clinical and clinical levels. The results will lay the groundwork for combinatorial trials with ONC201 for DIPG/DMG.
$450,000
$150,000
$150,000
$150,000
Dr. Javad Nazarian
Post Doctoral Fellowship
Dr. Antonella Petrović is the Yuvaan Tiwari Postdoctoral Fellow at the DIPG/DMG Center, University Children's Hospital Zurich. Dr. Petrović's research is dedicated to discovering novel combinatorial therapies for treatment of children diagnosed with diffuse midline gliomas. Working closely with Dr. Nazarian, she is assessing the efficacy of candidate drugs for targeting the PI3K pathway, a tumorigenic pathway most often activated in DMGs.
2023
2022
$250,000
$25,000
$200,000
N/A
The DIPG/DMG Collaborative is a cooperative effort of independent foundations from around the world to support long term DIPG/DMG research, eliminating duplication, enhancing transparency, and building cooperative channels. The shared mission is to efficiently fund and inspire DIPG/DMG research that may lead to homerun cures for the most elusive types of pediatric brain cancers.
$35,000
$5,000
$30,000
N/A
Founding member of the DDRFA and sponsor of the National Brain Tumor Board. The DDRFA collaboratively funds innovative research, access to trials, and data integration and utilization for DIPG/DMG, placing strategic investments to bring advances in treatment, eradication, diagnosis and prevention. The Tumor Board is a free consultation service provided to DIPG/DMG patients.
2021
$100,000
$100,000
Dr. Carl Koschmann
Research is being conducted on combinatorial targeting of H3 K27M-DMG/DIPG with ONC201 and EGFR inhibitors to determine:
1) The impact of EGFR pathway activation on FOXG1 signaling and mitochondrial bioenergetics in H3 K27M-DMG/DIPG
2) The ability of EGFR/FOXG1 modulation to impact mitochondrial bioenergetics and ONC201 sensitivity in H3 K27M-DMG/DIPG
2021
$100,000
$100,000
Dr. Matt Dun
2021
$118,000
$118,000
Dr. Sabine Mueller
A Clinical Research Coordinator was hired by Dr. Mueller to support research within the Pediatric Brain Tumor Center. The Coordinator supports the clinical pediatric neuro-oncology team in trial activation, trial management, data collection and data entry. The Coordinator also supports the collection and assessment of correlative studies such as imaging analyses.
2021
$75,000
$75,000
Dr. David Solomon
Research is being conducted on the discovery, functional analysis, and therapeutic targeting of novel oncogenes and tumor suppressor genes.
Dr. Michelle Monje | Stanford University
Dr. Matt Dun | University of Newcastle
Dr. Sabine Mueller | UCSF
Dr. Carl Koschmann | University of Michigan